These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 30360670

  • 21. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Barreca A, Fenoglio R, Baldovino S, Menegatti E.
    Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
    [Abstract] [Full Text] [Related]

  • 22. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M.
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [Abstract] [Full Text] [Related]

  • 23. Baseline characteristics and long-term outcomes of steroid-resistant nephrotic syndrome in children: impact of initial kidney histology.
    Watanabe Y, Fujinaga S, Endo A, Endo S, Nakagawa M, Sakuraya K.
    Pediatr Nephrol; 2020 Dec; 35(12):2377-2381. PubMed ID: 32964318
    [Abstract] [Full Text] [Related]

  • 24. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?
    Meyrier AY.
    Kidney Int; 2009 Sep; 76(5):487-91. PubMed ID: 19494796
    [Abstract] [Full Text] [Related]

  • 25. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS.
    Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
    [Abstract] [Full Text] [Related]

  • 26. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 27. [Nephrotic syndrome in minimal change disease (kidney), focal segmental glomerulosclerosis, and focal mesangioproliferative glomerulonephritis].
    Voznesenskaia TS, Sergeeva TV.
    Ter Arkh; 2002 Mar; 74(6):31-3. PubMed ID: 12136479
    [Abstract] [Full Text] [Related]

  • 28. [Nephrotic syndrome: Current understanding and future therapies].
    Diefenhardt P, Osterholt T, Brinkkötter P.
    Dtsch Med Wochenschr; 2022 Mar; 147(6):332-336. PubMed ID: 35291039
    [Abstract] [Full Text] [Related]

  • 29. Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome.
    Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q.
    Pediatr Nephrol; 2018 Jul; 33(7):1183-1187. PubMed ID: 29569191
    [Abstract] [Full Text] [Related]

  • 30. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.
    Dado D, Parikh S, Ayoub I, Rovin B, Nadasdy T, Hebert L.
    Clin Nephrol; 2018 May; 89(5):376-380. PubMed ID: 29249233
    [Abstract] [Full Text] [Related]

  • 31. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
    Han KH, Kim SH.
    Biomed Res Int; 2016 May; 2016():3053706. PubMed ID: 27195285
    [Abstract] [Full Text] [Related]

  • 32. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
    Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.
    Pediatr Nephrol; 2015 Mar; 30(3):469-77. PubMed ID: 25239302
    [Abstract] [Full Text] [Related]

  • 33. The treatment of idiopathic focal segmental glomerulosclerosis in adults.
    Hogan J, Radhakrishnan J.
    Adv Chronic Kidney Dis; 2014 Sep; 21(5):434-41. PubMed ID: 25168833
    [Abstract] [Full Text] [Related]

  • 34. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
    Suri M, Tran K, Sharma AP, Filler G, Grimmer J.
    Int Urol Nephrol; 2008 Sep; 40(3):807-10. PubMed ID: 18491215
    [Abstract] [Full Text] [Related]

  • 35. C1q nephropathy: a variant of focal segmental glomerulosclerosis.
    Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, D'Agati VD.
    Kidney Int; 2003 Oct; 64(4):1232-40. PubMed ID: 12969141
    [Abstract] [Full Text] [Related]

  • 36. Renal disease. II. The treatment of minimal change nephropathy and focal segmental glomerulosclerosis.
    Mason PD.
    J R Coll Physicians Lond; 1997 Oct; 31(2):137-41. PubMed ID: 9131509
    [No Abstract] [Full Text] [Related]

  • 37. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.
    Tune BM, Mendoza SA.
    J Am Soc Nephrol; 1997 May; 8(5):824-32. PubMed ID: 9176855
    [Abstract] [Full Text] [Related]

  • 38. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome.
    Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM.
    Am J Physiol Renal Physiol; 2021 Oct 01; 321(4):F505-F516. PubMed ID: 34459222
    [Abstract] [Full Text] [Related]

  • 39. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
    Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A.
    BMC Nephrol; 2016 Mar 31; 17():37. PubMed ID: 27036111
    [Abstract] [Full Text] [Related]

  • 40. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology.
    Meyrier A, Condamin MC, Broneer D.
    Clin Nephrol; 1991 Mar 31; 35 Suppl 1():S37-42. PubMed ID: 1860266
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.